CSPC Pharmaceutical (01093) said its profit attributable to shareholders for the six months ended 30 June 2017 rose 27.1% year-on-year to HK$1,313 million (or a 33.6% growth on a constant currency basis).
Basic and diluted earnings per share were HK21.69 cents.
Revenue amounted to HK$7,201.6 million, an increase of 17.2% from a year earlier (or a 23.2% growth on a constant currency basis). Gross profit grew 35.9% year-on-year to HK$4,125 million.
No interim dividend will be distributed.
WoW WoW星期三：健康網購產品低至$99 (只限今天)► 立即行動
